These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24853141)

  • 21. Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes.
    Ishizu-Higashi S; Seno H; Nishi E; Matsumoto Y; Ikuta K; Tsuda M; Kimura Y; Takada Y; Kimura Y; Nakanishi Y; Kanda K; Komekado H; Chiba T
    PLoS One; 2014; 9(5):e98017. PubMed ID: 24849253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study.
    Chun YS; Huang M; Rink L; Von Mehren M
    World J Surg Oncol; 2014 Jul; 12():231. PubMed ID: 25052889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
    Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
    J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
    Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
    Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
    Tamaki Y; Nakade Y; Yamauchi T; Makino Y; Yokohama S; Okada M; Aso K; Kanamori H; Ohashi T; Sato K; Nakao H; Haneda M; Yoneda M
    J Gastroenterol; 2013 Apr; 48(4):491-503. PubMed ID: 22886508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.
    Berkan-Kawińska A; Piekarska A
    Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714
    [No Abstract]   [Full Text] [Related]  

  • 28. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
    Argyrou C; Moris D; Vernadakis S
    J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.
    Nardo AD; Grün NG; Zeyda M; Dumanic M; Oberhuber G; Rivelles E; Helbich TH; Markgraf DF; Roden M; Claudel T; Trauner M; Stulnig TM
    Liver Int; 2020 Jul; 40(7):1620-1633. PubMed ID: 32281248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of nicotine on choline-deficient, L-amino acid-defined diet-induced non-alcoholic steatohepatitis in rats.
    Kanamori H; Nakade Y; Yamauchi T; Sakamoto K; Inoue T; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sumida Y; Nakao H; Fukuzawa Y; Yoneda M
    PLoS One; 2017; 12(6):e0180475. PubMed ID: 28662136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
    Bae CR; Zhang H; Kwon YG
    PLoS One; 2020; 15(12):e0243497. PubMed ID: 33275637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention by methionine of enhancement of hepatocarcinogenesis by coadministration of a choline-deficient L-amino acid-defined diet and ethionine in rats.
    Tsujiuchi T; Kobayashi E; Nakae D; Mizumoto Y; Andoh N; Kitada H; Ohashi K; Fukuda T; Kido A; Tsutsumi M
    Jpn J Cancer Res; 1995 Dec; 86(12):1136-42. PubMed ID: 8636001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.
    Okishio S; Yamaguchi K; Ishiba H; Tochiki N; Yano K; Takahashi A; Kataoka S; Okuda K; Seko Y; Liu Y; Fujii H; Takahashi D; Ito Y; Kamon J; Umemura A; Moriguchi M; Yasui K; Okanoue T; Itoh Y
    Sci Rep; 2020 Nov; 10(1):19578. PubMed ID: 33177546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.